Esperion Therapeutics Files 8-K for Regulation FD Disclosure
Ticker: ESPR · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $82.0 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-governance
TL;DR
**Esperion Therapeutics just dropped an 8-K for Regulation FD, signaling new info is out for everyone.**
AI Summary
Esperion Therapeutics, Inc. filed an 8-K on January 18, 2024, primarily to disclose information under Regulation FD, which ensures fair disclosure of material nonpublic information. This filing indicates that the company may have shared new, important information with certain individuals or groups, which it is now making public. For investors, this matters because it means there could be new developments regarding the company's operations, financial health, or drug pipeline that could influence the stock price, and all investors now have access to this information simultaneously.
Why It Matters
This filing ensures all investors have equal access to potentially market-moving information, preventing an unfair advantage for those who might have received it privately.
Risk Assessment
Risk Level: low — This filing is a standard disclosure and does not inherently indicate a negative event, but rather ensures transparency.
Analyst Insight
A smart investor would look for the specific information disclosed under Regulation FD, as this filing merely signals that such information has been made public. The actual impact depends on the content of that disclosure.
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — the date of the earliest event reported in the 8-K
- 001-35986 (null) — Commission File Number for Esperion Therapeutics, Inc.
- ESPR (null) — Trading Symbol for Esperion Therapeutics, Inc. Common Stock
- NASDAQ Stock Market (null) — exchange where Esperion Therapeutics, Inc. Common Stock is registered
FAQ
What is the primary purpose of Esperion Therapeutics, Inc.'s 8-K filing on January 18, 2024?
The primary purpose of Esperion Therapeutics, Inc.'s 8-K filing on January 18, 2024, is for 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', as indicated in the 'ITEM INFORMATION' section of the filing.
What is the trading symbol and the exchange where Esperion Therapeutics, Inc.'s common stock is registered?
Esperion Therapeutics, Inc.'s common stock has the trading symbol 'ESPR' and is registered on the 'NASDAQ Stock Market', as stated under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the business address and phone number of Esperion Therapeutics, Inc.?
The business address for Esperion Therapeutics, Inc. is '3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108', and their telephone number is '(734) 887-3903', according to the 'BUSINESS ADDRESS' and 'Registrant’s telephone number' sections.
What was Esperion Therapeutics, Inc.'s former company name and when did the name change occur?
Esperion Therapeutics, Inc.'s former company name was 'HDL THERAPEUTICS INC', and the date of the name change was '20080513', as detailed in the 'FORMER COMPANY' section.
Under which sections of the Securities Exchange Act of 1934 might this 8-K filing simultaneously satisfy other obligations?
The 8-K filing indicates it might simultaneously satisfy obligations under 'Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)', 'Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)', 'Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))', and 'Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))', as shown by the checked boxes.
Filing Stats: 891 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-01-18 16:03:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ESPR NASDAQ Stock Market
- $82.0 million — ents and short-term investments totaled $82.0 million as of December 29, 2023. This amount is
Filing Documents
- tm243338d1_8k.htm (8-K) — 28KB
- 0001104659-24-004800.txt ( ) — 197KB
- espr-20240118.xsd (EX-101.SCH) — 3KB
- espr-20240118_lab.xml (EX-101.LAB) — 33KB
- espr-20240118_pre.xml (EX-101.PRE) — 22KB
- tm243338d1_8k_htm.xml (XML) — 3KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and similar expressions, or the negative of these terms. These forward-looking statements include statements about the Company's preliminary financial results. Accordingly, these statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward- looking statements are qualified in their entirety by reference to the factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and in the Company's other reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 18, 2024 Esperion Therapeutics, Inc. By: /s/ Sheldon L. Koenig Sheldon L. Koenig President and Chief Executive Officer